Multi-parameter genomic assays, such as Oncotype DX and MammaPrint, are being used for patients with hormone receptor-positive (ER+/PgR+) and HER2- early breast cancer who may benefit from adding chemotherapy to adjuvant endocrine therapy[2,3]. This evidence concerns the gene PGR and breast cancer.